The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
Iris Lee; Liqing Wang; Andrew D Wells; Qunrui Ye; Rongxiang Han; Martin E Dorf; William A Kuziel; Barrett J Rollins; Lieping Chen; Wayne W Hancock (Profiled Author: Lieping Chen)
Department of Pathology and Laboratory Medicine, Joseph Stokes, Jr., Research Institute and Biesecker Pediatric Liver Center, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA 19104, USA.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(12):6929-35.
Islet allografts are subject to rapid rejection through host cellular immune responses involving mononuclear cell recruitment and tissue injury. Interruption of leukocyte recruitment through chemokine receptor targeting is of therapeutic benefit in various experimental models, but little is known about the contribution of chemokine pathways to islet allograft rejection. We found that murine islets produce monocyte chemoattractant protein-1 (MCP-1; CCL2) in vitro and that islet allograft rejection was associated with intragraft expression of MCP-1 and its receptor, CCR2. We therefore investigated whether MCP-1 and CCR2 are required for the rejection of fully MHC-disparate islet allografts. Wild-type mice treated with blocking anti-MCP-1 mAb plus a brief, subtherapeutic course of rapamycin had long-term islet allograft survival, in contrast to the effect of treatment with either mAb or rapamycin alone. CCR2(-/-) mice treated with rapamycin also maintained islet allografts long-term. Both MCP/CCR2- and rapamycin-sensitive signals were required for maximal proliferation of alloreactive T cells, suggesting that MCP-1/CCR2 induce rejection by promoting alloreactive T cell clonal expansion and homing and migration. Prolonged islet allograft survival achieved by blockade of the MCP-1/CCR2 pathway plus rapamycin therapy was accompanied by a mononuclear cell infiltrate expressing the inhibitory receptor, programmed death-1 (PD-1), and its ligand (PD-L1, B7-H1), and prolongation of islet allograft survival was abrogated by anti-PD-L1 mAb therapy. These data show that the blockade of MCP-1 binding to CCR2 in conjunction with subtherapeutic immunosuppression can have profound effects on islet allograft survival and implicate the expression of the PD-1/PD-L1 pathway in the regulation of physiologic responses in vivo.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Rezaul Karim; Ekaterina S Jordanova; Sytse J Piersma; Gemma G Kenter; Lieping Chen; Judith M Boer; Cornelis J M Melief; Sjoerd H van der BurgClinical cancer research : an official journal of the American Association for Cancer Research 2009;15(20):6341-7.
Monica V Goldberg; Charles H Maris; Edward L Hipkiss; Andrew S Flies; Lijie Zhen; Rubin M Tuder; Joseph F Grosso; Timothy J Harris; Derese Getnet; Katharine A Whartenby; et al.Blood 2007;110(1):186-92.
Takeshi Azuma; Sheng Yao; Gefeng Zhu; Andrew S Flies; Sarah J Flies; Lieping ChenBlood 2008;111(7):3635-43.
Appears in this Publication
Author of this Publication